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The major inﬂammatory bowel diseases, Crohn's disease and ulcerative colitis, are both debilitating
disorders of the gastrointestinal tract, characterized by a dysregulated immune response to unknown
environmental triggers. Both disorders have an important and overlapping genetic component, and
much progress has been made in the last 20 years at elucidating some of the speciﬁc factors contributing
to disease pathogenesis. Here we review our growing understanding of the immunogenetics of in-
ﬂammatory bowel disease, from the twin studies that ﬁrst implicated a role for the genome in disease
susceptibility to the latest genome-wide association studies that have identiﬁed hundreds of associated
loci. We consider the insight this offers into the biological mechanisms of the inﬂammatory bowel
diseases, such as autophagy, barrier defence and T-cell differentiation signalling. We reﬂect on these
ﬁndings in the context of other immune-related disorders, both common and rare. These observations
include links both obvious, such as to pediatric colitis, and more surprising, such as to leprosy. As a
changing picture of the underlying genetic architecture emerges, we turn to future directions for the
study of complex human diseases such as these, including the use of next generation sequencing
technologies for the identiﬁcation of rarer risk alleles, and potential approaches for narrowing down
associated loci to casual variants. We consider the implications of this work for translation into clinical
practice, for example via early therapeutic hypotheses arising from our improved understanding of the
biology of inﬂammatory bowel disease. Finally, we present potential opportunities to better understand
environmental risk factors, such as the human microbiota in the context of immunogenetics.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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The Inﬂammatory Bowel Diseases (IBD) are a group of inﬂam-
matory disorders affecting the gastrointestinal tract. The major
types are Crohn's disease (CD) and ulcerative colitis (UC). Neither
CD nor UC are fatal, but both are debilitating conditions: affected
patients experience a range of symptoms associated with inﬂam-
mation of the gut, including abdominal pain, fever, vomiting,
diarrhoea, rectal bleeding, anaemia and weight loss. There is
currently no known cure, but symptoms can be managed through
anti-inﬂammatory steroids or immunosuppressants to reduce
inﬂammation, dietary changes to try and remove environmental
triggers, and (in severe cases) surgery to remove damaged portions
of the bowel. Although CD and UC share a number of clinical fea-
tures, there are important distinctions in incidence patterns, dis-
ease localization, histopathology and endoscopic features (Table 1)
that suggest there are differences in the underlying pathways
driving each disease [1,2].
IBD prevalence is currently highest in Europe (UC, 505 per
100,000 persons; CD, 322 per 100,000 persons) and North
America (UC, 249 per 100,000 persons; CD, 319 per 100,000 per-
sons) [3]. It is more common in Ashkenazi Jews, who are ﬁve to
eight times more likely to develop IBD compared to non-Jewish
populations [4]. More broadly, global prevalence is rising, with
rapid increases in incidence rates occurring as more countries
adopt a ‘Westernised’ lifestyle [5]. Incidence rates are also rising in
younger people, placing an increased strain on healthcare re-
sources (particularly as early-onset IBD has been associated with a
higher risk of developing colorectal cancer) [6]. Overall, IBD rep-
resents a signiﬁcant global health burden that is of growing
concern.Table 1
Clinical and epidemiological features of the two major inﬂammatory bowel disease subt
Crohn's disease
Incidence patterns
Sex More common in women than men
Prevalence rates CD is more prevalent than UC
in developed countries
Disease localisation
Affected areas Entire gastrointestinal tract (from mouth to anus)
Inﬂammation pattern May occur as patchy, discontinuous inﬂammation
Histopathology
Penetrance Transmural inﬂammation of the entire bowel wall
Appearance Thickened colon wall with granulomas,
deep ﬁssures and a cobblestone appearance
Serological markers
Anti-Saccaromyces cerevisiae antibodies
Complications
Fistulas, abdominal mass (typically lower right quadrant),
colonic and small-bowel obstructions, stomatitis2. The early days of IBD genetics
2.1. Twin studies
IBD is characterised by a dysregulated immune response to
unknown environmental triggers in a genetically susceptible indi-
vidual, and a heritable component to the disease is well recognised.
Early epidemiological observations showed clear familial clus-
tering, which was reﬂected in high sibling risk ratios (UC, 7e17; CD,
15e42) [7]. Twin studies have since conclusively shown these ob-
servations to be due to genetics, rather than shared environmental
factors, by comparing disease concordance rates between pairs of
monozygotic (MZ) and dizygotic (DZ) twins, with the assumption
that both types of twin pair have roughly the same shared envi-
ronment, and thus variation in concordance can be attributed to
genetics. In a large meta-analysis of 6 twin studies the resulting
rates of 30.3% vs 3.6% for Crohn's disease (112MZ vs 196DZ), and
15.4% vs 3.9% for ulcerative colitis (143MZ vs 206DZ), support the
importance of genetics in IBD risk [8]. Motivated by these ﬁndings,
there have been a number of studies aimed at identifying the
speciﬁc genomic loci that explain IBD heritability. Ideally, each of
these associated loci would identify a single gene, or indeed a
causative genetic variant, to help understand the biological pro-
cesses of IBD.
2.2. Linkage studies
Initially, IBD genetics studies were by necessity coarse-grained,
as the high cost of sequencing and low throughput of genotyping
restricted data collection to just a handful of genetic variants within
a small number of individuals. The earliest studies thereforeypes, Crohn's disease and ulcerative colitis [1,2].
Ulcerative colitis
Equal rates in men and women
UC emerged before CD in developed countries, and is more prevalent
in still-developing countries
Colon, plus some potential backwash ileitis
Continuous inﬂammation in the affected area (though sometimes
a separate cecal patch)
Inﬂammation restricted to the mucosal and submucosal layers
(other than in fulminant colitis)
Distorted crypt architecture, with shallow erosions and ulcers; granulomas,
if present, only around crypts
Anti-neutrophil cytoplasmic antibodies
Haematochezia, passage of mucus or pus, fulminant colitis and toxic megacolon
Fig. 1. Biological summary of pathways involved in inﬂammatory bowel disease, highlighting the roles of some of the key IBD-associated genes. A) The signalling pathways through
which NOD2 responds to microbial peptidoglycan stimuli to promote innate mucosal defence and an autophagic response; adapted from Philpott et al. (2014) [26]. B) The IL23R
signalling pathway used to activate the adaptive immune response, and the downstream TH17 cell differentiation program [43,53,86,102]. ATG5, autophagy protein 5; ATG12,
autophagy-related protein 12; ATG16L1, autophagy-related protein 16-1; ERK, extracellular signal-related kinase; IL-22, interleukin 22; LC3, ubiquitin-like protein LC3; MEKK4,
mitogen-activated protein kinase/ERK kinase kinase 4; NF-kB, nuclear factor kB; NOD2, nucleotide-binding oligomerization domain-containing protein 2; RIP2, receptor-interacting
protein 2.
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markers evenly distributed across the genome were sufﬁcient to
capture the pattern of DNA inheritance within a family [9]. By
tracing the DNA segments that segregate with disease status (such
as variant alleles only seen in affected individuals, and not in their
unaffected relatives), sections of the genome that confer risk to the
disease can be identiﬁed. This linkage analysis approach is good for
detecting highly penetrant variants (i.e. those that are extremely
likely to cause disease whenever present) that segregate well with
disease status.
Linkage studies successfully identiﬁed many such highly pene-
trant variants for rare disorders [10e16], and were subsequently
applied to a range of more common diseases. In 1996, the ﬁrst such
study in IBD linked a portion of chromosome 16 (dubbed ‘IBD1’)
with Crohn's disease [17], which was successfully replicated in
subsequent studies [18e23]. This ﬁnding was followed up using
more closely packed markers within a small number of genes, and
the IBD1 region on chromosome 16was found to be caused by three
disease risk alleles in the gene NOD2, whose role in the recognition
of bacterial peptidoglycans and subsequent stimulation of animmune response supports its likely association with the devel-
opment of CD (Fig. 1A) [24e26]. These variants were especially
common in Ashkenazi Jews, partially explaining the increased
burden of CD in that group. Unfortunately, however, successes like
NOD2 were rare: it remained one of the few robustly replicated
genetic risk loci discovered via linkage, not just in IBD, but across
common diseases.
2.3. Limitations of linkage studies and the common disease,
common variant hypothesis
The widespread disappointment from linkage results among
common diseases reﬂected a fundamental property of their genetic
architecture: these diseases did not have a single, highly penetrant
genetic cause. Instead, it was proposed by Risch and Merikangas
(1996) that complex diseases were driven by the accumulation of
many risk factors of only modest effect (the ‘common disease,
common variant’ hypothesis). Finding associations via linkage un-
der this scenario is difﬁcult, as the genetic risk may be spread
throughout the genome rather than concentrated in a single locus
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population-level allele frequencies of cases and controls are sta-
tistically different) is muchmore powerful, provided it is possible to
choose the right variant to test among the millions known to exist
in the human population. Risch and Merikangas (1996) calculated
that 17,997 affected sibling pairs would be needed to detect a risk
allele with 50% frequency and an odds ratio of 1.5 using linkage, as
opposed to just 484 using an association analysis.
3. The GWAS era
3.1. Technological developments that made GWAS possible
Case-control association studies could detect signals tooweak to
show linkage, but suffered the drawback of needing to knowwhich
variants to test. One solution to this problem was to select candi-
date genes, based on prior biological hypotheses, but this produced
a deluge of association claims with weak statistical evidence that
did not replicate in subsequent studies [28]. This failure to ﬁnd
robust genetic associations in biological candidates highlighted a
repeated theme of genetic studies that can scan the entire genome
in an unbiased way producing unexpected insights.
Three developments upended this stasis in gene discovery, and
fundamentally changed gene mapping. First, by 2005, the public
database of the most common type of genetic variant, single
nucleotide polymorphisms (SNPs, where a single letter of DNA is
variable) contained 9.2 million sites that had been catalogued by
projects such as the SNP Consortium and the International HapMap
Consortium [29,30]. Second, these catalogues of population-level
genetic variation had also shown that variants common in the
general population (minor allele frequency [MAF] > 5%), and in
physical proximity, were highly correlated, or in linkage disequi-
librium (LD), with each other. Human population history had left a
pattern of long LD blocks of high correlation, separated by small
‘hotspots’ where most historical recombination events tended to
cluster [31]. This uneven LD pattern meant that it was possible to
test the majority of common variants by carefully selecting markers
in each long LD block. Approximately 500,000 well chosen SNPs
could capture nearly 5 million common SNPs in Europeans and East
Asians; unsurprisingly, the more genetically diverse African pop-
ulations required almost twice as many markers to capture the
same amount of variation [32]. Finally, in the mid-2000s, it became
economically feasible to genotype hundreds of thousands of vari-
ants using new microarray technologies. These key advances
opened the way for genome-wide association studies (GWAS) that
could be used to detect the diverse genomic loci associated with a
given complex trait. GWAS combined the hypothesis-free ability to
scan the whole genome of linkage with the statistical power to
detect associations of smaller effect size.
3.2. GWAS: A revolution in IBD genetics
Crohn's disease was among the ﬁrst diseases studied using
GWAS, beginning in 2006. In addition to conﬁrming the established
NOD2 association, these early studies [33e36] identiﬁed four new
loci at genome-wide levels of statistical signiﬁcance (p < 5  108),
demonstrating the power of the GWAS approach. The strongest
new association was a protective variant in IL23R, which encodes a
receptor protein embedded in the cell membrane of many different
types of immune cells and, upon binding of IL23, starts a signalling
cascade that promotes inﬂammation and coordinates an adaptive
immune response (Fig.1B) [33]. Amore surprising discoverywas an
association to a protein-coding variant in ATG16L1, which encodes a
protein involved in the autophagosome pathway (Fig. 1A) [34], and
provided the ﬁrst evidence for the importance of autophagy in CD.This pathway is responsible for processing intracellular bacteria,
and so the ATG16L1 association contributed to further under-
standing of dysfunction of the intestinal barrier in Crohn's disease.
Finally, these early studies discovered a pair of associations on
chromosomes 5p13 and 10q21 that were far from any genes
[35,36]. Unlike the previous associations, these new results high-
lighted the important role of regulatory and non-coding elements
in complex disease. Motivated by these early successes, further
GWAS used increasingly larger sample sizes to implicate both the
innate (NKX2-3, CARD9) and adaptive (TNFSF15, PTPN2, IL-12B)
immune response pathways in inﬂammatory bowel disease, and
recapitulate the role of autophagy and intracellular bacteria man-
agement (NOD2, ATG16L1, IRGM) in Crohn's disease [37].
These initial CD studies also suggested a partial overlap of ge-
netic risk for ulcerative colitis: of the Crohn's disease associations
discovered, about 30% were also found to be associated with UC via
replication studies [9]. Additional GWAS in ulcerative colitis cohorts
lead to the discovery of multiple novel UC-speciﬁc loci [38e41].
Three loci with roles in intercellular interactions were identiﬁed,
suggesting epithelial barrier defects may play a role in UC-speciﬁc
pathogenesis: HNF4A, which encodes a transcription factor regu-
lating the expression of components in the cellecell junction;
CDH1, which produces a transmembrane glycoprotein that is
crucial to the adherens junction compartment and has also been
associated with colorectal cancer susceptibility, and; LAMB1, which
encodes the b1 subunit of a laminin, the major noncollagenous
components of basement membranes [41].
These UC-speciﬁc studies also conﬁrmed the long-established
association between UC and the classical human leukocyte anti-
gen (HLA) locus [42], which contains genes encoding antigen-
presenting proteins on the surface of the cell, and plays a crucial
role in the regulation of the adaptive immune system. Despite the
HLA being strongly associated with many other chronic inﬂam-
matory and autoimmune disorders, the association with CD is
much weaker [43]. The pattern of association to IBD in the HLA
region is the most complicated in the genome. While the most
recent study of HLA in IBD conclusively showed that the HLA-
DRB1*01:03 allele is the most strongly associated in both CD and
UC, it also identiﬁedmore than ten additional risk alleles associated
with one or both diseases [44]. Most of these associations are
disease-speciﬁc; HLA class I and class II variation contributes
equally to CD, class II variation is more important in ulcerative
colitis. In addition, evidence of decreased heterozygosity in HLA
genes was observed for ulcerative colitis only. This non-additive
effect (similar to that observed in HLA alleles associated with
Type 1 diabetes [45]) highlights the importance of being able to
detect a wide range of antigens for protective immunity.
3.3. Meta-analyses and the importance of sample size
While this ﬂurry of discoveries generated new biological hy-
potheses for IBD, it became clear that these relatively weak asso-
ciations cumulatively explained only a fraction of the heritability
expected from twin studies. This ‘missing heritability’ problemwas
universal amongst complex diseases during the early GWAS era,
and was partially attributed to types of variation not captured by
GWAS (e.g. non-European, rare and structural variants) [46,47]. As
Fig. 2 shows, these early studies were actually poorly powered
because the true genetic architecture of IBD includes many variants
with odds ratios <1.2 or even 1.1. The International IBD Genetics
Consortium (IIBDGC) was formed to pool thousands of already
genotyped samples from previous GWAS to search for these small
effects. Comparisons among different genotyping chips was
enabled by imputation, which infers missing data by comparing
known genotypes to those in a representative reference set with
Fig. 2. Power to detect associations of different effect size (odds ratio, OR) are compared for common variants (MAF ¼ 0.2, panel A) and rare variants (MAF ¼ 0.01, panel B). Effective
sample sizes of several key studies are indicated along the x-axis, to reﬂect the power of the GWAS studies (blue), meta-analyses (green) and Immunochip-based studies (yellow)
[93].
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sources [30,48].
The ﬁrst of these IIBDGC meta-analyses effectively tripled the
number of known Crohn's disease susceptibility loci with the
identiﬁcation of 21 novel associations, including another autophagy
gene (LRRK2) [49]. This was followed by a meta-analysis of ulcer-
ative colitis studies, which identiﬁed 29 new UC risk loci, and a
second Crohn's disease meta-analysis that brought the number of
CD susceptibility loci to 71 [50,51]. This rapid accumulation of IBD
risk loci culminated in 2012 with a meta-analysis containing over
75,000 cases (including both CD and UC for the ﬁrst time) andTable 2
Example pathways implicated in inﬂammatory bowel disease pathogenesis. Genes belong
where these overlap with other immune-mediated disorders are marked. Note however
many loci contain multiple candidate genes, these should not be treated as conﬁrmed [5
Pathway implicated Pathway genes in
IBD-associated loci
Overlap with other immu
Ankolysing
spondylitis
Psoriasis
Innate immune response
Epithelial barrier
function and repair
CDH1, ERRFI1, GNA12,
HNF4A, ITLN1, MUC19,
NKX2-3, PLA2G2E, PTGER4,
REL, STAT3
NKX2-3, PTGER4 REL
Innate mucosal defence CARD9, FCGR2A, IL18RAP, ITLN1,
NOD2, REL, SLC11A1
CARD9, FCGR2A REL
Autophagy ATG16L1, CUL2, DAP, IRGM,
LRRK2, NOD2, PARK7
e e
Apoptosis/necroptosis DAP, FASLG, MST1, PUS10, THADA e e
Activation of adaptive immune response
IL23-R response pathway CCR6, IL12B, IL21, IL23R, JAK2,
STAT3, STAT4, TYK2
IL12B, IL23R,
JAK2, TYK2
IL12B, IL2
STAT3, TY
NF-kB NFKB1, REL, TNFAIP3, TNIP1 e NFKB1, R
TNFAIP3,
Aminopeptidases ERAP1, ERAP2 ERAP1, ERAP2 ERAP1, ER
IL2 and IL-21 T-cell
activation
IL2, IL21, IL2RA e e
Regulation of adaptive immune response
Th17 cell differentiation AHR, CCR6, IL2, IL22, IL23R, IRF4,
JAK2, RORC, STAT3, TNFSF15, TYK2
IL23R, JAK2,
TYK2
IL23R, TY
T-cell regulation ICOSLG, IFNG, IL12B, IL2, IL21,
IL23R, IL2RA, IL7R, NDFIP1, PIM3,
PRDM1, TAGAP, TNFRSF9, TNFSF8
ICOSLG, IL12B,
IL23R
IL12B, IL2
TAGAP
B-cell regulation BACH2, IKZF1, IL5, IL7R, IRF5 BACH2 econtrols, that brought the total number of IBD loci to 163 [52].
Numerous pathways were implicated through multiple genetic
associations, including those involved in innate mucosal defence,
JAK/STAT signalling, cytokine production (particularly interferon-g,
interleukin (IL)-12, tumour-necrosis-factor-a and IL10 signalling)
and lymphocyte activation.
This dramatic growth in the number of IBD-associated loci,
together with the ﬁrst large-scale joint analyses of CD and UC,
revealed that genetic risk for CD and UC substantially overlap.
Although early GWAS data had suggested quite disparate under-
lying pathways, of the 163 loci identiﬁed in the Jostins et al. (2012)ing to these pathways and falling within IBD-associated loci are indicated, and cases
that in some cases the speciﬁc genes have not yet been identiﬁed as causal and, as
2,53,63,86,94e101].
ne-mediated disorders
Coeliac Rheumatoid
arthritis
Type 1
diabetes
Systemic lupus
erythematosus
Multiple
sclerosis
REL REL - - PTGER4,
STAT3
IL18RAP, REL FCGR2A, REL FCGR2A,
IL18RAP
FCGR2A FCGR2A
e e e e e
PUS10 e e e e
3R,
K2
IL21, STAT4 CCR6, IL21,
STAT4, TYK2
TYK2 STAT4, TYK2 IL12B, STAT3,
STAT4, TYK2
EL,
TNIP1
REL, TNFAIP3 REL, TNFAIP3 TNFAIP3 TNFAIP3, TNIP1 NFKB1
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Fig. 3. The number of IBD-associated loci identiﬁed using various study designs over
the past ﬁfteen years.
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the 30 CD-speciﬁc and 23 UC-speciﬁc loci, 43 show the same di-
rection of effect in the non-associated disease suggesting that only
a tiny minority truly have zero effect in the other disease. This
considerable overlapping genetic risk implies that the two diseases
shared many biological mechanisms. The few loci that are CD- or
UC-speciﬁc, as well as the relative size of effects at shared loci,
might reveal clues about the distinct pathologies of the two
diseases.
3.4. IBD genetics in the context of other diseases
Understanding both the shared and private genetics of related
disorders can be useful for constructing hypotheses about the un-
derlying biological pathways that may be driving each disease, and
how distinct clinical phenotypes may arise. For example, known
IBD loci are enriched for genes involved in primary immunodeﬁ-
ciencies, including those linked to reduced levels of circulating T
cells (ADA, CD40, TAP1, TAP2, NBN, BLM, DNMT3B), and to T-helper
cells responsible for producing TH17, memory, and regulatory Tcells
(STAT3, SP110, STAT5B). It thus became clear that the same genes can
be affected by damaging protein coding variants that cause these
severe disorders as well as much more subtle (presumed regula-
tory) variants that slightly affect risk of complex diseases like IBD.
Several studies have also extended these cross-disease genetic
comparisons to potentially related complex diseases, such as the
common immune-mediated disorders (ankylosing spondylitis,
coeliac disease, multiple sclerosis, psoriasis, rheumatoid arthritis,
systemic lupus erythematosus, and type I diabetes). Early analysis
of GWAS results from across these diseases (and IBD) suggested
that the innate immune response, as well as the general immune
pathways involved in T-cell differentiation and signalling, are
shared between many of them (Table 2) [43]. This observed
overlap of risk loci among common immune mediated diseases
then motivated the design of a new genotype array, called
Immunochip, which contained markers densely covering loci
selected for their known association with at least one of 11
immune-mediated diseases, or their suggestive signiﬁcance in the
early immune-related GWAS studies. This targeted array, which
cost approximately 20% of the price of contemporary GWAS chips,
made the genotyping of large samples of immune-mediated dis-
orders possible, and also paved the way for more extensive disease
subphenotype and cross-disease studies [53]. Indeed, the Immu-
nochip formed the basis of the Jostins et al. (2012) IBD meta-
analysis, which showed that 70% (113 out of 163) of the IBD loci
identiﬁed are also shared with other complex diseases or traits,
including 66 loci shared with other immune-mediated disorders.
Sharing is particularly strong between IBD and the other sero-
negative diseases, ankylosing spondylitis and psoriasis. Interest-
ingly, across the immune-mediated diseases those loci that are not
shared tend to have large effect sizes, which would explain why
the genetic underpinnings of CD and UC appeared so misleadingly
disparate prior to the large meta-analysis efforts [53]. Overlap
with more distantly related diseases can also provide useful in-
sights. For example, Jostins et al. (2012) observed an enrichment in
genes previously linked with Mendelian susceptibility to myco-
bacterial disease (MSMD) and leprosy (a complex mycobacterial
disease): these overlaps suggest that the genetic architecture of
IBD may have been shaped by selection pressures arising from
mycobacterial infection [52].
3.5. Expanding into non-European populations
Up until this point, GWAS in IBD had largely focused on samples
of European ancestry. One notable exception was a Crohn's diseasestudy in 2005 [54], performed in a Japanese population after it was
noted that NOD2 did not appear to play a signiﬁcant role in the
pathogenesis of CD in Japan [55e57]. This study identiﬁed a strong
association between the gene TNFSF15 and CD despite an initial
sample size of fewer than 100 patients. Additional IBD genome
wide association studies within Indian, Japanese and Korean pop-
ulations showed that most IBD genetic risk is shared regardless of
ancestry [58e62], but many of these studies were small, preventing
informative comparisons across populations.
A large IBD study of multiple ancestries was conducted by the
IIBDGC both to study IBD associations apparently unique to one
population, and to boost power for detection in all populations
using meta-analysis techniques that account for population
stratiﬁcation. GWAS and Immunochip data were analysed from
96,486 individuals of European, East Asian, Indian and Iranian
descent, yielding a total of 200 IBD associated regions [63]. For
the vast majority of these loci, the direction and magnitude of the
effect is consistent between the European and non-European
cohorts, implying that the underlying casual variants at these
shared loci are likely to be common, as rare alleles are more likely
to be population-speciﬁc. For the handful of associations that
appear to be heterogeneous between populations, nearly all are
due to differences in allele frequency between populations. For
example, NOD2 is not biologically less relevant in Japan, but
rather the IBD risk variants are simply absent in that population.
Only TNFSF15 (which exhibits microbial-induced expression [64])
and the autophagy gene ATG16L1 are common in all populations
but appear to have different effect sizes, possibly reﬂecting dif-
ferences in geneeenvironment interactions between the
populations.
4. Beyond GWAS
Both the meta-analyses and trans-ancestry studies contributed
to an almost 20-fold increase in the number of known IBD-
associated loci (Fig. 3). However, as with many complex diseases,
this approach of analysing ever-larger genotype array-based
datasets still captures only the fraction of IBD heritability
explained by common variants, mostly in European populations.
In fact, the latest estimates by Chen et al. (2014) suggest that
common variants explain only 26% of the heritability of Crohn's
disease, and 19% of the heritability of ulcerative colitis [65]. Some
of this missing heritability may be found in regions sometimes
Fig. 4. Effect sizes of IBD-associated loci identiﬁed using various study designs. The
largest effect sizes are seen for the ﬁrst two genes associated with IBD, NOD2 and
IL23R. Nevertheless, the genes SMAD7 and ITGAL, which have relatively small effect
sizes, are both conﬁrmed drug targets.
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study by Chang et al. (2014) utilized X-chromosome data from
existing datasets to identify a new IBD-associated gene, ARHGEF6,
which interacts with a major surface protein on Helicobacter pylori
(a gastric bacterium) [66]. Rare loss-of-function variants in the X-
chromosome gene XIAP, which encodes a protein that inhibits
apoptosis, have also been identiﬁed as strongly predisposing for
early-onset Crohn's disease in males [67,68]. However, uncovering
rare variants associated with complex disease will require the
development of new study designs, as they generally have low
correlation to the marker SNPs used (which usually have much
higher allele frequencies, MAF > 0.05, to better capture other
common variation) and are therefore not well tagged [69].
4.1. Rare and low frequency variation
To successfully identify a rare or low frequency disease-
associated allele it is necessary to directly test the variant site it-
self, as such variants are not in high LD with many others, pre-
venting the capture of its signal by a proxy variant (the method
which drove the success of GWAS). Furthermore, because such al-
leles are by deﬁnition observed infrequently in the population,
even the largest catalogues of human variation are unlikely to
contain all variants of interest. Instead, discovery tends to require
sequencing of an entire region (not just the known variable sites),
something that became possible with the emergence of next gen-
eration sequencing (NGS) technology.
In its infancy, NGS was still prohibitively expensive, so
sequencing was limited to a handful of genes in small numbers of
samples. One approach to maximize the effectiveness of IBD
sequencing studies was to consider early-onset IBD, as the XIAP
studies did. Early-onset IBD tends to be more severe, and may be
more similar to single-gene, or Mendelian, disorders than adult-
onset IBD. Glocker et al. (2009) identiﬁed rare mutations affecting
IL10R protein subunits using a combination of linkage analysis and
candidate gene sequencing in early-onset IBD cases from unrelated
consanguineous families [70]. Similarly, Blaydon et al. (2011)
identiﬁed a rare loss-of-function mutation in the gene ADAM17
(necessary for the cleavage of the epithelial-cell mitogen TGF-a
from the cell membrane) that was homozygous in a consanguin-
eous sibling pair affected by inﬂammatory bowel disease and skin
lesions [71]. As the cost of sequencing started to fall, several studies
used NGS to search for rare and low frequency variation in candi-
date IBD loci across case control cohorts. One of the earliest such
studies sequenced 56 candidate genes identiﬁed by GWAS in 350
CD cases and 350 controls (with follow up genotyping in tens of
thousands of IBD patients), identifying four additional risk variants
in NOD2, two protective variants in IL23R, and a protective splice
variant in CARD9 [72]. A similar study of 55 candidate genes in 200
UC cases and 150 controls recapitulated the presence of rare vari-
ants in CARD9 and IL23R, and identiﬁed a newassociation in RNF186
[73].
Just as was seen during the GWAS era, the logical next step is to
scale these candidate-gene sequencing studies up to genome-wide
projects: however, deep sequencing of whole genomes across suf-
ﬁciently large case/control cohorts is still too expensive. Because
the minor allele of a given rare variant is observed so infrequently,
obtaining a signiﬁcantly large difference in MAF between cases and
controls is not possible with achievable sample sizes (Fig. 2). One
approach is to use burden testing, which reduces the number of
samples needed to detect a rare variant association by aggregating
information across all variants in a given target region (such as a
gene or exon). Every occurrence of a variant at any position in the
region contributes to the overall count, and the difference in these
counts between cases and controls is then tested as though theywere from a single site of variation. In this way, rare variant asso-
ciations can be detected with sample sizes that are more compa-
rable to those used to test common variation.
Despite this, obtaining sufﬁciently large sequenced datasets is
still difﬁcult. Zuk et al., [2014] suggest at least 25,000 cases and an
equivalent number of controls are needed for awell-powered study
[74]. While ultimately whole genome sequencing will become
affordable, two distinct intermediate approaches exist to sequence
large numbers of individuals. First, borrowing the most popular
approach in Mendelian genetics, is to only sequence the so-called
exome (all exons, or coding regions, in the genome), as this rep-
resents just 1% of the complete genome [75]. However, the majority
of IBD-associated loci identiﬁed during the GWAS era actually lie in
non-coding regions, and it is likely that rare variants affecting gene
regulatory pathways will be of interest. The second design is to
spread a ﬁxed amount of sequence data across the whole genomes
of many individuals. This produces lower quality data per individ-
ual, but the increased sample size improves power to detect low
frequency and rare variation in a ﬁxed-cost study [76]. As an added
advantage, such cohorts of sequenced individuals then provide
useful disease-speciﬁc reference panels for imputing rare variants
into new and existing GWAS datasets.4.2. Identifying the casual mutations
With 200 loci associated with Crohn's disease and ulcerative
colitis over the past two decades, and the promise of more to come
as next generation sequencing studies grow, attention is now
turning to the identiﬁcation of casual genes and variants within
these loci (ﬁne-mapping). Historically, follow-up of genetic asso-
ciations has proceeded via time-consuming experimental valida-
tion of proposed genes using cellular or mouse models. While such
functional evidence is essential to fully understanding the biology
implicated by genetics, it is also possible to leverage the huge
sample sizes put together for GWAS to improve ﬁne-mapping
before undertaking these experiments. Currently, attempts are
being made to ﬁne-map casual variants in a high-throughput way
using the IIBDGC's large Immunochip cohorts, aiming to replicate
the success seen in coeliac disease, where the densely packed
markers on the Immunochip were used to narrow approximately
half of the known signals to an individual gene (or even subregions
of genes in some cases) [77]. Further prioritisation of candidate
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notations from projects such as ENCODE [78], samples from mul-
tiple populations (as LD patterns differ between groups of differing
ancestry), and combined datasets of huge sample size. Various al-
gorithms have been developed to rank variants within a locus
[79,80], but no deﬁnitive method for identifying the disease risk
allele exists.
A recent study by Farh et al. (2015) highlights some of the po-
tential challenges in ﬁne-mapping loci given the current knowledge
of the effects of different types of genetic variation, with the obser-
vation that asmuch as 90% of causal IBD variantsmay be non-coding.
It was noted that, while casual variants often occurred near the
binding sites of master regulators of immune differentiation and
stimulus-dependent gene activation, only 10e20% alter a known
transcription-factor binding motif [79]. Gaining a more complete
understanding of this regulatory code remains an important chal-
lenge in both IBD and complex disease genetics more generally.
5. Prospects for translation
5.1. Informing treatment
IBD susceptibility genes have already been shown to have
important applications in the development of new treatments. A
notable case is the associated locus near SMAD7, which has been
shown to reduce the activity of TGF-b1 (an immunosuppressive
cytokine) when present at high levels. In a recent phase 2 trial of an
oral SMAD7 antisense oligonucleotide, mongersen, Crohn's disease
patients receiving the drug had signiﬁcantly higher remission rates
than those given a placebo [81]. Similarly, the drug Efalizumab
targets the product of ITGAL, an integrin aL subunit of lymphocyte
function-associated antigen 1 (LFA-1), and has been used to treat
psoriasis. A brief, open-label study of Efalizumab for treating
Crohn's disease showed evidence of a clinical response in the ma-
jority of subjects [82]. Notably, the effect sizes of these clinically
relevant genes are relatively small (Fig. 4), highlighting the
importance of continuing to catalogue IBD-associated loci to build
up a complete picture of disease pathogenesis and susceptibility.
As well as uncovering potential targets for therapeutic devel-
opment, identiﬁed genetic associations can also prove useful in
determining clinical subphenotypes and predicting disease course.
For example, in Crohn's disease, associations have been found be-
tween the HLA and colonic CD [83], while NOD2 variants have been
shown to predict ileal location and the need for CD-related surgery
[84]. Similarly, for ulcerative colitis the HLA is associated with
extensive disease and colectomy [85]. Such information can be used
to construct individual genetic risk scores, which summarize pre-
dictions about disease risk and likely progression based on a pa-
tient's speciﬁc genetic proﬁle. Techniques like this can then help to
identify misdiagnosed patients and drive more personalized
treatment approaches.
5.2. Environmental factors: The microbiome
Another area that offers particular promise for the translation of
genetic ﬁndings into clinical practice is investigation into the
interaction between an individual's genome and their environ-
ment. In the case of IBD, loci identiﬁed to date have provided strong
evidence of a role for the gut microbiota in disease pathogenesis,
with the epithelial barrier and autophagy pathways repeatedly
implicated [86]. Microbiome studies in IBD have shown there are
distinct differences in the composition of the gut ﬂora in diseased
and healthy individuals, such as a decrease in bacteroides, ﬁrmi-
cutes, ruminococcaceae and biﬁdobacterium, and an increase in the
presence of Escherichia coli and fusobacterium [87]. However, causeand effect are difﬁcult to disentangle: did the disturbed micro-
biome arise as a result of the extensive inﬂammatory response, or
did it trigger it? The effects of therapeutics on the intestinal envi-
ronment further complicate such questions, as treatments such as
antibiotics are known to affect the gut microbial community
[88,89]. Finally, even amongst healthy individuals the precise
composition of the microbiome is extremely sensitive to diet and
other unknown environmental factors: family observations show
that sharing both genetics and a living space is no guarantee of a
completely shared microbiome, and even within the same indi-
vidual temporal variations are observed [90].
The importance of understanding the role of the microbiome is
reﬂected in the recent success of fecal microbiota transplants
(FMTs) as a treatment for inﬂammatory bowel disease. FMTs aim to
reduce dysbiosis in the bowel by modifying the microbiome using
stool from a healthy donor. Although the idea was ﬁrst introduced
by Eiseman et al., in 1958 to treat pseudomembranous enterocolitis
[91], it has only recently gained popular attention from the IBD
community. An initial study by Suskind et al. (2015) showed tem-
porary remission in seven of nine patients, and more extended
remission in ﬁve of those cases. Efﬁcacy of the FMT depended on
whether it successfully engrafted or not, and on how similar the
recipient's original microbiome was to the donor one [92]. Despite
this early success, further clinical studies are required to properly
evaluate the safety and efﬁcacy of this method.
6. Summary
For more than twenty years the study of genetics has held
promise for understanding the causes of IBD. Over that span it
became clear that its substantial heritability would not be
explained by a handful of heavy hitters, like NOD2, but by the cu-
mulative contribution of hundreds of genetic variants of small ef-
fect. While this means the prospect of genetic diagnosis of IBD (or
indeed any complex auto-inﬂammatory disorder) is distant, the
accumulation of these genetic clues has steadily improved our
understanding of disease biology. The overlap of risk loci between
CD and UC underscores their shared pathways and points to a
subtle molecular classiﬁcation of IBD that may only be partially
represented by current clinical deﬁnitions. The factors that separate
the two disorders, likely involving distinct genetic risk factors,
tissue speciﬁc stimuli or differential response to environmental
triggers remain unresolved. More broadly, genetics offers insight
into the relationship of IBD to other immune and inﬂammatory
disorders, both common and rare, including surprises such as the
overlap with leprosy that may point to the evolutionary history of
genes that must strike a balance between defence and self-damage.
As the biological pathways implicated by genetics become clearer,
and new studies inevitably lead to new discoveries of rarer risk
alleles, the progress in understanding IBD genetics will provide the
foundation for progress in developing IBD therapies.
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